Advertisement


Michael J. Overman, MD, on Colorectal Cancer: Updated Results From CheckMate 142

2017 Gastrointestinal Cancers Symposium

Advertisement

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on nivolumab alone or in combination with ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability high metastatic colorectal cancer (Abstract 519).



Related Videos

Gastrointestinal Cancer

Masanori Terashima, MD, PhD, on Gastric Cancer: Results of the JCOG1001 Trial

Masanori Terashima, MD, PhD, of Shizuoka Cancer Center, discusses phase III study findings evaluating bursectomy for patients with subserosal/serosal gastric cancer (Abstract 5).

Hepatobiliary Cancer

Julien Edeline, MD, on Biliary Tract Cancer: Results of the PRODIGY 12-ACCORD 18 Trial (French Language Version)

Julien Edeline, MD, of the Centre Eugène Marquis, discusses in French study findings on gemcitabine and oxaliplatin vs surveillance following surgery for localized biliary tract cancer (Abstract 225).

Colorectal Cancer

Cathy Eng, MD, on Anal Squamous Cell Cancer: Management Strategies

Cathy Eng, MD, of The University of Texas MD Anderson Cancer Center, discusses management approaches to anal cancer, including the current standard of care, as well as novel approaches for locally advanced and metastatic disease.

Colorectal Cancer

Scott Kopetz, MD, on Colorectal Cancer: Results of the SWOG 1406 Trial

Scott Kopetz, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (Abstract 520).

Hepatobiliary Cancer

Julien Edeline, MD, on Biliary Tract Cancer: Results of the PRODIGY 12-ACCORD 18 Trial

Julien Edeline, MD, of the Centre Eugène Marquis, discusses study findings on gemcitabine and oxaliplatin vs surveillance following surgery for localized biliary tract cancer (Abstract 225).

Advertisement

Advertisement




Advertisement